<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01241019</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2010-018627-25</org_study_id>
    <nct_id>NCT01241019</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia</brief_title>
  <acronym>NeoNATI</acronym>
  <official_title>Safety and Efficacy of Oral Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia: a Pilot Study of the Neonatal Neuroprotection of Asphyxiated Tuscan Infants (NeoNATI) Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Meyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Meyer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the administration of topiramate to
      newborns with hypoxic-ischemic encephalopathy potentiates the neuroprotective effect of
      treatment with hypothermia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonatal hypoxic-ischemic encephalopathy, due to perinatal asphyxia, is one of the leading
      causes of cerebral palsy, whose incidence, despite improvements in perinatal practice and
      neonatal care, has remained essentially unchanged over the recent past decades. It occurs
      approximately in 2-3 newborns every 1000 live births with a mortality rate of 10% for mild
      degrees and 60% for severe degrees. About 30% of survivors with mild hypoxic-ischemic
      encephalopathy and 100% with severe hypoxic-ischemic encephalopathy exhibit variable degrees
      of neurological disability.

      Several studies have demonstrated the therapeutic effects of whole-body or selective head
      cooling to treat neonates with hypoxic-ischemic encephalopathy. Mild hypothermia, (rectal or
      esophageal temperature 33-34Â°C), started within 6 h after birth and protracted for 48-72 h,
      can significantly improve primary outcome measures such as death or disability at 18 months
      or improve the neurological outcome in survivors. Consequently, mild hypothermia is at
      present recommended for the treatment of moderate degrees of encephalopathy.

      Topiramate an anticonvulsant agent widely used in adults and children, has been demonstrated
      to posses neuroprotective properties against hypoxic ischemic brain damage, both in vitro and
      in animal models and has been included in neuroprotective strategies for ischemic stroke and
      neonatal hypoxic-ischemic cerebral injury. Recently, topiramate treatment in asphyxiated
      newborns has been reported safe.

      Aim of the present study is to confirm the safety and to evaluate whether the association of
      topiramate enhances the neuroprotective properties of hypothermia for the treatment of
      neonatal hypoxic-ischemic encephalopathy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary aim is to evaluate the neurological outcome at 6, 12, 18 months of life</measure>
    <time_frame>18 months of life</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary aim is to evaluate the efficacy of treatment with topiramate for improving neuroradiological outcome at 3 and 12 months of life</measure>
    <time_frame>12 months of life</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Hypoxic Ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia and topiramate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia</intervention_name>
    <description>TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.</description>
    <arm_group_label>Topiramate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gestational age &gt; 36 weeks and birth weigh &gt; 1800 g with at least 1 of the following:
             a) Apgar score &lt; 5 at 10 minutes; b) persisting need for resuscitation, including
             endotracheal intubation or mask ventilation 10 minutes after birth; c) acidosis (pH
             &lt;7.0, base deficit &gt;-16 mmol/L in umbilical cord blood or arterial, venous or
             capillary blood) within 60 minutes from birth;

          2. moderate to severe encephalopathy, consisting of altered state of consciousness
             (irritability, lethargy, stupor, or coma) and &gt; 1 of the following sings: a)
             hypotonia, b) abnormal reflexes, including oculomotor or pupil abnormalities, c)
             absent or weak suck, d) clinical seizures.

          3. abnormal aEEG

        Exclusion Criteria:

        congenital abnormalities, congenital viral infections or evidence encephalopathy other than
        HIE.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>36 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Filippi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria A. Meyer, Firenze, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit - Azienda Ospedaliero-Universitaria Meyer</name>
      <address>
        <city>Florence</city>
        <zip>I-50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit - Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>I-56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://druginfo.nlm.nih.gov/</url>
    <description>Drug information</description>
  </link>
  <reference>
    <citation>Filippi L, la Marca G, Fiorini P, Poggi C, Cavallaro G, Malvagia S, Pellegrini-Giampietro DE, Guerrini R. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia. 2009 Nov;50(11):2355-61. doi: 10.1111/j.1528-1167.2009.02302.x. Epub 2009 Sep 10.</citation>
    <PMID>19744111</PMID>
  </reference>
  <reference>
    <citation>Filippi L, Poggi C, la Marca G, Furlanetto S, Fiorini P, Cavallaro G, Plantulli A, Donzelli G, Guerrini R. Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study. J Pediatr. 2010 Sep;157(3):361-6. doi: 10.1016/j.jpeds.2010.04.019. Epub 2010 May 31.</citation>
    <PMID>20553846</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Meyer</investigator_affiliation>
    <investigator_full_name>Luca Filippi</investigator_full_name>
    <investigator_title>Dr. Luca Filippi</investigator_title>
  </responsible_party>
  <keyword>asphyxia neonatorum, hypothermia, neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

